GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » COGS-to-Revenue

Revive Therapeutics (XCNQ:RVV) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics COGS-to-Revenue?

Revive Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was C$0.00 Mil.

Revive Therapeutics's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Revive Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was N/A%.


Revive Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Revive Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics COGS-to-Revenue Chart

Revive Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Revive Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revive Therapeutics COGS-to-Revenue Calculation

Revive Therapeutics's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Revive Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revive Therapeutics  (XCNQ:RVV) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Revive Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Revive Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Revive Therapeutics (XCNQ:RVV) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Executives
Michael Frank Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines